XJB-5-131|cas:866404-31-1|西域试剂

XJB-5-131,98.0%

产品编号：Bellancom-129460| CAS NO：866404-31-1| 分子式：C₅₃H₈₁N₇O₉| 分子量：960.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-129460	￥2600.00	杭州北京（现货）
Bellancom-129460	￥7800.00	杭州北京（现货）
Bellancom-129460	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

XJB-5-131

产品介绍

XJB-5-131 是一种靶向线粒体的 ROS 和电子清除剂。XJB-5-131 是双功能抗氧化剂，包含自由基清除剂。XJB-5-131 是针对线粒体的合成抗氧化剂。XJB-5-131 是有效的脐带血单核细胞 (CB MNC) 电离辐射保护剂和缓和剂。

生物活性

XJB-5-131 is a mitochondria-targeted ROS and electron scavenger. XJB-5-131 is a bi-functional antioxidant that comprises a radical scavenger. XJB-5-131 is a synthetic antioxidant that targets mitochondria. XJB-5-131 is an effective ionizing irradiation protector and mitigator of cord blood mononuclear cells (CB MNCs).

体外研究

XJB-5-131 also ameliorates hemorrhagic shock (HS)-induced activation of the pro-apoptotic enzymes, caspases 3 and 7, in ileal mucosa.
XJB-5-131 reduces apoptosis and enhances cell survival in mouse embryonic cells in vitro.
XJB-5-131 is a radiation protector for colony-forming unit-granulocyte macrophage (CFU-GM). XJB-5-131 is an effective mitigator when added after irradiation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Low density mononuclear cells (MNC)
Concentration:	10 μM
Incubation Time:	Added to cells one hour before irradiation or immediately after irradiation
Result:	Was a protector when given before irradiation as shown by an increase in the D0 to 1.93±0.13 for CFU-GM with XJB-5-131.

体内研究
(In Vivo)

XJB-5-131 ameliorates peroxidation of the mitochondrial phospholipid, cardiolipin, in ileal mucosal samples from rats subjected to hemorrhagic shock (HS) .
Intravenous treatment with XJB-5-131 (2 μmol/kg) significantly prolongs the survival of rats subjected to profound blood loss (33.5 mL/kg) despite administration of only a minimal volume of crystalloid solution (2.8 mL/kg) and the absence of blood transfusion.
XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains mitochondrial DNA copy number, suppresses motor decline and weight loss, enhances neuronal survival, and improves mitochondrial function. XJB-5-131 significantly suppresses the disease phenotypes and improves mitochondrial function in a mouse model of Huntington’s disease (HD) .
XJB-5-131 (1 mg/kg; intraperitoneally injected; three times a week up to 57 weeks) suppresses decline of weight loss and motor function in a mouse model of HD.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male specific pathogen-free Sprague-Dawley rats, weighing 150 to 250 g
Dosage:	2 μmol/kg
Administration:	Administered intravenously using a syringe pump
Result:	The rats treated with XJB-5-131 survived significantly longer (P < 0.01). Three of six survived for longer than 3 hours after completion of the hemorrhage protocol and one rat survived for the whole 6 hours postbleeding observation period.

Animal Model:	HD150KI mice
Dosage:	1 mg/kg
Administration:	Intraperitoneally injected; three times a week up to 57 weeks
Result:	Chronic treatment suppressed weight loss. Increased the average body mass by 22%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male specific pathogen-free Sprague-Dawley rats, weighing 150 to 250 g
Dosage:	2 μmol/kg
Administration:	Administered intravenously using a syringe pump
Result:	The rats treated with XJB-5-131 survived significantly longer (P < 0.01). Three of six survived for longer than 3 hours after completion of the hemorrhage protocol and one rat survived for the whole 6 hours postbleeding observation period.

Animal Model:	HD150KI mice
Dosage:	1 mg/kg
Administration:	Intraperitoneally injected; three times a week up to 57 weeks
Result:	Chronic treatment suppressed weight loss. Increased the average body mass by 22%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male specific pathogen-free Sprague-Dawley rats, weighing 150 to 250 g
Dosage:	2 μmol/kg
Administration:	Administered intravenously using a syringe pump
Result:	The rats treated with XJB-5-131 survived significantly longer (P < 0.01). Three of six survived for longer than 3 hours after completion of the hemorrhage protocol and one rat survived for the whole 6 hours postbleeding observation period.

Animal Model:	HD150KI mice
Dosage:	1 mg/kg
Administration:	Intraperitoneally injected; three times a week up to 57 weeks
Result:	Chronic treatment suppressed weight loss. Increased the average body mass by 22%.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (130.17 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.0414 mL	5.2070 mL	10.4140 mL
5 mM	0.2083 mL	1.0414 mL	2.0828 mL
10 mM	0.1041 mL	0.5207 mL	1.0414 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (2.17 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.17 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.17 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.17 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。